Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 98

Results For "Risk"

1561 News Found

Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets

This combination medicine is used to treat high blood pressure (hypertension).


NATCO launches generic Pomalidomide Capsules in Canada
News | March 01, 2023

NATCO launches generic Pomalidomide Capsules in Canada

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules


LifeSigns launches smart ward with wireless patient monitoring technology
News | March 01, 2023

LifeSigns launches smart ward with wireless patient monitoring technology

Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State


India hospital network launched to initiate life-saving colon cancer trial
News | February 28, 2023

India hospital network launched to initiate life-saving colon cancer trial

Twelve hospitals across India will be part of the network which will support the trial in India


ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
News | February 28, 2023

ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens

First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China


EMA recommends refusal of the marketing authorization for Lagevrio
News | February 25, 2023

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.


Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Drug Approval | February 23, 2023

Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial


Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio
News | February 22, 2023

Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio

The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies


New data confirm survival benefits of darolutamide in patients with metastatic hormone-sensitive prostate cancer
Clinical Trials | February 21, 2023

New data confirm survival benefits of darolutamide in patients with metastatic hormone-sensitive prostate cancer

New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)


Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI